GlassScriptPhysician profile
Timothy Charles Keys
NPI 1760471197
$13,705.65
in general payments reported to CMS, 2019-2025
42 companies · $3,118 in 2025
The $3,118 reported for 2025 was more than what 83% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $469 · 2020: $2,128 · 2021: $1,675 · 2022: $1,979 · 2023: $2,034 · 2024: $2,303 · 2025: $3,118.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,113 · Consulting Fee: $200 · Education: $142.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,112.80 |
| Consulting Fee | $200.00 |
| Education | $142.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $2,789.29 | 2020-2025 | Trelegy Ellipta, Nucala |
| Astrazeneca Pharmaceuticals LP | $2,000.80 | 2020-2025 | Fasenra, Tezspire, Breztri |
| Genzyme Corporation | $933.03 | 2021-2025 | |
| Olympus Corporation of The Americas | $901.13 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $896.46 | 2020-2025 | Ofev, Spiriva Respimat, Stiolto Respimat |
| Regeneron Healthcare Solutions, INC. | $839.11 | 2020-2025 | Dupixent |
| Cook Incorporated | $646.25 | 2020 | |
| Grifols USA, LLC | $559.01 | 2020-2025 | Prolastin-C Liquid |
| Insmed, INC. | $499.98 | 2020-2025 | Arikayce, Brinsupri |
| Mallinckrodt Hospital Products INC. | $446.51 | 2022-2025 | Acthar |
| Amgen INC. | $438.27 | 2022-2025 | Tezspire |
| Actelion Pharmaceuticals US, INC. | $428.82 | 2021-2025 | Uptravi, Opsumit |
| Bayer Healthcare Pharmaceuticals INC. | $373.83 | 2021-2023 | |
| Mylan Specialty L.P. | $291.56 | 2020-2024 | Yupelri |
| Viatris Specialty LLC | $178.18 | 2025 | Yupelri |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| United Therapeutics Corporation | $156.11 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $154.34 | 2024-2025 | Winrevair, Zerbaxa |
| Verona Pharma, INC. | $124.16 | 2025 | Ohtuvayre |
| Intuitive Surgical, INC. | $123.75 | 2024 | |
| Ani Pharmaceuticals, INC. | $97.07 | 2023-2025 | Purified Cortrophin Gel |
| Gilead Sciences, INC. | $76.58 | 2021-2022 | |
| Ethicon INC. | $58.57 | 2022 | |
| Janssen Pharmaceuticals, INC | $56.40 | 2021 | |
| Electromed, INC. | $51.25 | 2022-2023 | Smartvest |
| Paratek Pharmaceuticals, INC. | $51.11 | 2021 | |
| Philips North America LLC | $46.96 | 2023-2025 | Vest Therapy Und |
| Pulmonx Corporation | $46.60 | 2021-2023 | Chartis Catheter, Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console |
| E.R. Squibb & Sons, L.L.C. | $45.61 | 2020-2022 | |
| Pfizer INC. | $41.39 | 2022-2024 | |
| Genentech USA, INC. | $40.89 | 2022-2023 | Xolair |
| Teva Pharmaceuticals USA, INC. | $40.23 | 2021 | |
| Baxter Healthcare | $38.72 | 2025 | Hillrom - Vest System Model 105 Home Care |
| Novartis Pharmaceuticals Corporation | $33.69 | 2022-2023 | |
| Fisher & Paykel Healthcare INC | $30.45 | 2021 | |
| Livanova USA, INC. | $30.10 | 2020 | |
| Melinta Therapeutics, LLC | $27.23 | 2023 | Vabomere, Rezzayo, Kimyrsa |
| Liquidia Technologies, INC. | $22.60 | 2025 | Yutrepia |
| Acacia Pharma INC | $20.30 | 2021 | |
| La Jolla Pharmaceutical Company | $19.77 | 2025 | Giapreza |
| Inogen, INC. | $16.93 | 2024 | |
| Phadia US INC. | $16.70 | 2022 | |
| Astellas Pharma US INC | $15.91 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Keys listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.